Apollomics (APLM) Total Non-Current Liabilities (2021 - 2025)
Apollomics (APLM) posted quarterly Total Non-Current Liabilities of $3.6 million for Q4 2025, up 328.26% year-on-year from $835000.0 in Q4 2024, and down 29.12% on a QoQ basis from $5.0 million in Q2 2025.
Apollomics (APLM) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
Apollomics (APLM) has reported Total Non-Current Liabilities for 5 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 328.26% year-over-year to $3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.6 million (up 328.26% YoY) and the FY2025 annual result came in at $3.6 million, up 328.26% from the prior year.
- Total Non-Current Liabilities eased to $3.6 million in Q4 2025 per APLM's latest filing, from $5.0 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for APLM reached as high as $512.2 million in Q4 2022 and fell as low as $597000.0 in Q4 2023.
- A 5-year average of $106.0 million and a median of $2.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities tumbled 99.88% — and 2025, when it surged 351.66%.
- Year by year, Total Non-Current Liabilities stood at $322.7 million in 2021, then surged by 58.71% to $512.2 million in 2022, then slumped by 99.88% to $597000.0 in 2023, then soared by 39.87% to $835000.0 in 2024, then jumped by 328.26% to $3.6 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $3.6 million, $5.0 million, and $835000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Apollomics | 2.66 Bn | 2.66 Bn | - | 3.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.58 Mn |
| Jun 30, 2025 | 5.05 Mn |
| Dec 31, 2024 | 835,000.00 |
| Jun 30, 2024 | 1.12 Mn |
| Dec 31, 2023 | 597,000.00 |
| Jun 30, 2023 | 1.55 Mn |
| Dec 31, 2022 | 512.24 Mn |
| Dec 31, 2021 | 322.74 Mn |